Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone or Placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana

NCT00743145
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Inactive Marijuana (0% THC), Active Marijuana (5.5% THC), Active Marijuana (6.2% THC), Naltrexone, Placebo naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Opioid Modulation and Neural Reward Activation in Healthy Adults

NCT04854551
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use, Unspecified
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

NCT00142844
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders
Interventions
Naltrexone, Disulfiram, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

NCT01462227
View directory record Official record
Conditions
Hypoglycemia
Interventions
Naltrexone High Dose, Naltrexone Low Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Endophenotype for Alcohol Misuse in Healthy Minority Populations

NCT00256451
View directory record Official record
Conditions
Healthy
Interventions
Naltrexone, placebo, alcohol, Sham alcohol
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Naltrexone in Kleptomania

NCT00332579
View directory record Official record
Conditions
Kleptomania
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenetic Response to Naltrexone For Alcohol Dependence

NCT00831272
View directory record Official record
Conditions
Alcohol Dependence
Interventions
naltrexone, Placebo
Drug
Lead sponsor
David Oslin
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Danville, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

NCT00332605
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Naltrexone plus N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Results available

Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep

NCT05458609
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Lemborexant 10 mg, Naltrexone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 4 Interventional

Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)

NCT00000437
View directory record Official record
Conditions
Alcoholism, Smoking
Interventions
Naltrexone Tablet and Nicotine Patch, Naltrexone Tablet and Placebo Patch, Placebo Tablet and Nicotine Patch, Placebo Tablet and Placebo Patch
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 6, 2026, 7:28 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

NCT00419731
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Bupropion + Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention

NCT01227044
View directory record Official record
Conditions
Reduction in Heavy Drinking in Patients With HIV
Interventions
Naltrexone, Placebo + Medication Management/Medication Coaching
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cocaine Use Reduction With Buprenorphine

NCT01402492
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buprenorphine + Naltrexone, Placebo + Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Chronic Pain From Arthritis

NCT03008590
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCT00793780
View directory record Official record
Conditions
Obesity, Schizophrenia, Schizoaffective Disorder
Interventions
Naltrexone 25mg, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

Low Dose Naltrexone for Glioma Patients

NCT01303835
View directory record Official record
Conditions
Malignant Glioma
Interventions
LDN, Placebo
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers

NCT00502216
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Naltrexone, Varenicline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

NCT01825447
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Oxycodone + Naltrexone, Oxycodone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional Results available

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

NCT03194555
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Low-Dose Naltrexone and Acetaminophen Combination, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 2 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

NCT03061734
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 6, 2026, 7:28 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Naltrexone HCl 50 MG Oral Tablet, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 6, 2026, 7:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Treatment for Pathologic Gambling Disorder

NCT00053677
View directory record Official record
Conditions
Gambling
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 6, 2026, 7:28 AM EDT